- 4 week dosing schedule 1 INITIAL DOSING: 600 mg/day (3 tablets of 200 mg) KISQALI in combination with a NSAI Please refer to the Summary of Product Characteristics (SmPC) of the aromatase inhibitor for...Twitter Linkedin Facebook Pinterest Google plus
Reimbursement
Kisqali ® is reimbursed in Belgium, you can find the reimbursement conditions on the INAMI website .
E-HealthYou can request reimbursement by...
Twitter Linkedin Facebook Pinterest Google plusMechanism of action
Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-...
Twitter Linkedin Facebook Pinterest Google plusPatient Information
Indication
KISQALI is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as...
Twitter Linkedin Facebook Pinterest Google plusEfficacy
The efficacy of Kisqali has been investigated in various studies. The following pictures summarize all the main data’s from the MONALEESA 2, 3, 7 studiesTwitter Linkedin Facebook Pinterest Google plusSafety Profile
As with every medicine, when using Kisqali, side effects can occur. In the case of serious or unacceptable side effects, it is possible that a dose adjustment is necessary. Here you can read more about the side effects of Kisqali. The Majority of AEs...Twitter Linkedin Facebook Pinterest Google plusPatient Resources
Patient information leaflet ExjadeThe official patient information leaflet for EXJADE contains important information about its use and possible side effects. Patients can ask for the patient information leaflet at any time and...
Twitter Linkedin Facebook Pinterest Google plusPatient Resources
Revolade